Skip to main content
. 2020 Oct;8(20):1296. doi: 10.21037/atm-20-5856

Figure 3.

Figure 3

Effect of miR-103a-3p on immune disorder in OGD-treated BV2 cells by targeting HMGB1. (A) Effects of miR-103a-3p overexpression on the levels of TNF-α, IL-1β, IL-4, and IL-10 expression in OGD-stimulated BV2 microglial cells. (B) Effects of HMGB1 interference on the levels of TNF-α, IL-1β, IL-4, and IL-10 expression in OGD-stimulated BV2 microglial cells. (C) Effects of miR-103a-3p and HMGB1 overexpression on the levels of TNF-α, IL-1β, IL-4, and IL-10 expression in OGD-stimulated BV2 microglial cells (*, P<0.05; **, P<0.01 versus the control group; #, P<0.05 versus the miR-103a-3p NC group; ##, P<0.01 versus the miR-103a-3p NC group; &&, P<0.01 versus the miR-103a-3p mimic group). OGD, oxygen-glucose deprivation; HMGB1, high mobility group box 1; TNF-α, tumor necrosis factor-alpha; IL-1β, interleukin-1beta; IL-4, interleukin-4; IL-10, interleukin-10.